

## Table of Contents

|                      |             |
|----------------------|-------------|
| <b>Preface</b> ..... | <b>xvii</b> |
|----------------------|-------------|

|                               |             |
|-------------------------------|-------------|
| <b>About the Editor</b> ..... | <b>.xix</b> |
|-------------------------------|-------------|

### DONOR QUALIFICATION

|                                |          |
|--------------------------------|----------|
| <b>Donor Eligibility</b> ..... | <b>1</b> |
|--------------------------------|----------|

*Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)*

|                             |   |
|-----------------------------|---|
| Case Scenario .....         | 1 |
| Questions and Answers ..... | 1 |
| Key Takeaways .....         | 3 |
| Suggested Readings .....    | 3 |

|                           |          |
|---------------------------|----------|
| <b>Donor Safety</b> ..... | <b>4</b> |
|---------------------------|----------|

*Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)*

|                             |   |
|-----------------------------|---|
| Case Scenario .....         | 4 |
| Questions and Answers ..... | 4 |
| Key Takeaways .....         | 5 |
| Suggested Readings .....    | 6 |

|                                          |          |
|------------------------------------------|----------|
| <b>Ineligible Allogeneic Donor</b> ..... | <b>7</b> |
|------------------------------------------|----------|

*Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)*

|                             |   |
|-----------------------------|---|
| Case Scenario .....         | 7 |
| Questions and Answers ..... | 7 |
| Key Takeaways .....         | 8 |
| Suggested Readings .....    | 8 |

|                                                                                                           |           |
|-----------------------------------------------------------------------------------------------------------|-----------|
| <b>Haploidentical Stem Cell Transplantation in a Patient with<br/>Donor-Specific HLA Antibodies</b> ..... | <b>10</b> |
|-----------------------------------------------------------------------------------------------------------|-----------|

*Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)*

|                                   |    |
|-----------------------------------|----|
| Background .....                  | 10 |
| Case Scenario .....               | 10 |
| Questions and Answers .....       | 10 |
| Analysis and Considerations ..... | 11 |

|                                                                                           |           |
|-------------------------------------------------------------------------------------------|-----------|
| Key Takeaways . . . . .                                                                   | 12        |
| Suggested Readings . . . . .                                                              | 12        |
| <b>Allogeneic Donor Hematopoietic Progenitor Cell Collection Considerations . . . . .</b> | <b>13</b> |
| <i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)</i>                                        |           |
| Case Scenario . . . . .                                                                   | 13        |
| Questions and Answers . . . . .                                                           | 13        |
| Key Takeaways . . . . .                                                                   | 14        |
| Suggested Readings . . . . .                                                              | 15        |
| <b>COLLECTION OF STARTING MATERIAL</b>                                                    |           |
| <b>A Case of Good Collection . . . . .</b>                                                | <b>17</b> |
| <i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)</i>                                        |           |
| Case Scenario . . . . .                                                                   | 17        |
| Questions and Answers . . . . .                                                           | 17        |
| Key Takeaways . . . . .                                                                   | 19        |
| Suggested Readings . . . . .                                                              | 19        |
| <b>Mononuclear Cell Collections . . . . .</b>                                             | <b>20</b> |
| <i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)</i>                                        |           |
| Case Scenario . . . . .                                                                   | 20        |
| Questions and Answers . . . . .                                                           | 20        |
| Key Takeaways . . . . .                                                                   | 23        |
| Suggested Readings . . . . .                                                              | 23        |
| <b>Apheresis Collection Challenges for Patients with Hemoglobinopathy . . . . .</b>       | <b>24</b> |
| <i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)</i>                                        |           |
| Case Scenario . . . . .                                                                   | 24        |
| Questions and Answers . . . . .                                                           | 24        |
| Key Takeaways . . . . .                                                                   | 28        |
| Suggested Readings . . . . .                                                              | 29        |
| <b>A Case of Poor Marrow Yield, Part 1 . . . . .</b>                                      | <b>30</b> |
| <i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB)</i>                                        |           |
| Case Scenario . . . . .                                                                   | 30        |

|                                                                                                                |           |
|----------------------------------------------------------------------------------------------------------------|-----------|
| Questions and Answers. . . . .                                                                                 | 30        |
| Key Takeaways. . . . .                                                                                         | 31        |
| Suggested Readings. . . . .                                                                                    | 32        |
| <b>A Case of Poor Marrow Yield, Part 2 . . . . .</b>                                                           | <b>33</b> |
| <i>Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)</i>                                                             |           |
| Background . . . . .                                                                                           | 33        |
| Case Scenario . . . . .                                                                                        | 33        |
| Questions and Answers. . . . .                                                                                 | 34        |
| Analysis and Considerations . . . . .                                                                          | 34        |
| Key Takeaways . . . . .                                                                                        | 35        |
| Suggested Readings. . . . .                                                                                    | 35        |
| <b>PROCESSING/MANUFACTURING</b>                                                                                |           |
| <b>Novel Cellular Products: Third-Party Manufacturing Issues . . . . .</b>                                     | <b>37</b> |
| <i>Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB)</i>                                              |           |
| Case Scenario . . . . .                                                                                        | 37        |
| Questions and Answers. . . . .                                                                                 | 38        |
| Key Takeaways . . . . .                                                                                        | 40        |
| Suggested Readings. . . . .                                                                                    | 40        |
| <b>When the Freezer Falts: A Case of Storage Equipment<br/>Temperature Fluctuations . . . . .</b>              | <b>42</b> |
| <i>Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB)</i>                                              |           |
| Case Scenario . . . . .                                                                                        | 42        |
| Questions and Answers. . . . .                                                                                 | 43        |
| Key Takeaways . . . . .                                                                                        | 45        |
| Suggested Readings. . . . .                                                                                    | 45        |
| <b>A Case of TNC Recovery and Postthaw Viability: Negative<br/>Trend in Cord Blood Manufacturing . . . . .</b> | <b>46</b> |
| <i>Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB)</i>                                              |           |
| Case Scenario . . . . .                                                                                        | 46        |
| Questions and Answers. . . . .                                                                                 | 46        |
| Key Takeaways . . . . .                                                                                        | 48        |
| Suggested Readings. . . . .                                                                                    | 49        |

**Legit or Quit? (Unauthorized Stem Cell Treatments) . . . . .50**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB)*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 50 |
| Questions and Answers . . . . . | 50 |
| Key Takeaways . . . . .         | 52 |
| Suggested Readings . . . . .    | 53 |

**ADVERSE EVENTS**

**Acute Hemolytic Reaction Following Infusion of a Marrow Graft in a Patient with Sickle Cell Disease . . . . .55**

*Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB), DABRM, FABRM*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 55 |
| Questions and Answers . . . . . | 56 |
| Key Takeaways . . . . .         | 58 |
| Suggested Readings . . . . .    | 59 |

**Acute Hemolytic Reaction during ABO-Major-Incompatible Marrow Transplantation . . . . .60**

*Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB), DABRM, FABRM*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 60 |
| Questions and Answers . . . . . | 61 |
| Immediate management: . . . . . | 62 |
| Specific therapy: . . . . .     | 62 |
| Key Takeaways . . . . .         | 63 |
| Suggested Readings . . . . .    | 64 |

**SHIPPING/DISTRIBUTION/LABELING**

**Shipping for Further Manufacturing . . . . .65**

*Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)*

|                                                          |    |
|----------------------------------------------------------|----|
| Background . . . . .                                     | 65 |
| Case Scenario . . . . .                                  | 65 |
| Questions and Answers . . . . .                          | 66 |
| Questions and Answers for Noncontract Shipping . . . . . | 67 |
| Analysis and Considerations . . . . .                    | 68 |

|                                                                                                          |           |
|----------------------------------------------------------------------------------------------------------|-----------|
| Key Takeaways . . . . .                                                                                  | 68        |
| Suggested Readings. . . . .                                                                              | 68        |
| <b>To Release or Not Release . . . . .</b>                                                               | <b>69</b> |
| <i>Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)</i>                                                       |           |
| Case Scenario . . . . .                                                                                  | 69        |
| Questions and Answers. . . . .                                                                           | 69        |
| Key Takeaways . . . . .                                                                                  | 72        |
| Suggested Readings. . . . .                                                                              | 72        |
| <b>Expired Incoming Cell Product . . . . .</b>                                                           | <b>73</b> |
| <i>Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)</i>                                                       |           |
| Background . . . . .                                                                                     | 73        |
| Case Scenario . . . . .                                                                                  | 73        |
| Questions and Answers. . . . .                                                                           | 74        |
| Key Takeaways . . . . .                                                                                  | 75        |
| Suggested Readings. . . . .                                                                              | 76        |
| <b>Obscured Label on Incoming Cryopreserved HPC(A) Product . . . . .</b>                                 | <b>77</b> |
| <i>Indira Guleria, PhD, D(ABHI), CABP(H)(AABB)</i>                                                       |           |
| Background . . . . .                                                                                     | 77        |
| Case Scenario . . . . .                                                                                  | 77        |
| Questions and Answers. . . . .                                                                           | 78        |
| Key Takeaways . . . . .                                                                                  | 78        |
| Suggested Readings. . . . .                                                                              | 79        |
| <b>ENVIRONMENTAL MONITORING</b>                                                                          |           |
| <b>Environmental Monitoring and Temperature Excursion in a<br/>GMP Cell Therapy Laboratory . . . . .</b> | <b>81</b> |
| <i>Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB),<br/>DABRM, FABRM</i>                      |           |
| Case Scenario . . . . .                                                                                  | 81        |
| Questions and Answers. . . . .                                                                           | 82        |
| Key Takeaways . . . . .                                                                                  | 85        |
| Suggested Readings. . . . .                                                                              | 85        |

**System Failure in Critical Environmental Monitoring: A “Groundhog Day” Scenario in the Cell Processing Laboratory . . . . .86**

*Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB),  
DABRM, FABRM*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 86 |
| Questions and Answers . . . . . | 86 |
| Key Takeaways . . . . .         | 89 |
| Suggested Readings . . . . .    | 90 |

**EQUIPMENT AND SUPPLIES**

**Critical Supply Shortage Combined with QC Testing of Cellular Therapy Equipment and Products . . . . .91**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 91 |
| Questions and Answers . . . . . | 91 |
| Key Takeaways . . . . .         | 94 |
| Suggested Readings . . . . .    | 94 |

**When Good Equipment Goes Bad . . . . .95**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                 |    |
|---------------------------------|----|
| Case Scenario . . . . .         | 95 |
| Questions and Answers . . . . . | 95 |
| Key Takeaways . . . . .         | 98 |
| Suggested Readings . . . . .    | 98 |

**Apheresis Equipment Failure . . . . .99**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                 |     |
|---------------------------------|-----|
| Case Scenario . . . . .         | 99  |
| Questions and Answers . . . . . | 99  |
| Key Takeaways . . . . .         | 101 |
| Suggested Readings . . . . .    | 102 |

## **A Case of Managing Supply Chain Interruptions . . . . . 103**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 103 |
| Questions and Answers. . . . . | 103 |
| Key Takeaways . . . . .        | 106 |
| Suggested Readings. . . . .    | 106 |

## **Sterility Testing Crisis in Cell Therapy Manufacturing Combined with “Here We Go Again, It’s Another Drug Shortage” . . . . . 107**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 107 |
| Questions and Answers. . . . . | 108 |
| Key Takeaways . . . . .        | 110 |
| Suggested Readings. . . . .    | 110 |

## **QUALITY ASSURANCE**

### **Contaminated Marrow Products: Discovery, Investigation, Corrective Action, and Follow Up . . . . . 111**

*Ronit Reich-Slotky, PhD, MS, CABP(AABB)*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 111 |
| Questions and Answers. . . . . | 111 |
| Key Takeaways . . . . .        | 114 |
| Suggested Readings . . . . .   | 114 |

### **Fresh Infusion of Allogeneic Products with a Positive Microbial Culture Result . . . . . 115**

*Ronit Reich-Slotky, PhD, MS, CABP(AABB)*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 115 |
| Questions and Answers. . . . . | 115 |
| Key Takeaways . . . . .        | 120 |
| Suggested Readings. . . . .    | 120 |

### **A Broken Cryobag . . . . . 121**

*Ronit Reich-Slotky, PhD, MS, CABP(AABB)*

|                         |     |
|-------------------------|-----|
| Case Scenario . . . . . | 121 |
|-------------------------|-----|

|                                                                              |            |
|------------------------------------------------------------------------------|------------|
| Questions and Answers . . . . .                                              | 121        |
| Key Takeaways . . . . .                                                      | 125        |
| Suggested Readings . . . . .                                                 | 125        |
| <b>Engraftment Failure Investigation . . . . .</b>                           | <b>126</b> |
| <i>Ronit Reich-Slotky, PhD, MS, CABP(AABB)</i>                               |            |
| Case Scenario . . . . .                                                      | 126        |
| Questions and Answers . . . . .                                              | 126        |
| Key Takeaways . . . . .                                                      | 128        |
| Suggested Readings . . . . .                                                 | 128        |
| <b>A Case of One Donor for Two Recipients . . . . .</b>                      | <b>130</b> |
| <i>Ronit Reich-Slotky, PhD, MS, CABP(AABB)</i>                               |            |
| Case Scenario . . . . .                                                      | 130        |
| Questions and Answers . . . . .                                              | 130        |
| Key Takeaways . . . . .                                                      | 132        |
| Suggested Readings . . . . .                                                 | 132        |
| <b>Apheresis Equipment System Error . . . . .</b>                            | <b>134</b> |
| <i>Ronit Reich-Slotky, PhD, MS, CABP(AABB)</i>                               |            |
| Case Scenario . . . . .                                                      | 134        |
| Questions and Answers . . . . .                                              | 134        |
| Key Takeaways . . . . .                                                      | 137        |
| Suggested Readings . . . . .                                                 | 137        |
| <b>Validating a Cellular Therapy Laboratory Information System . . . . .</b> | <b>138</b> |
| <i>Ronit Reich-Slotky, PhD, MS, CABP(AABB)</i>                               |            |
| Case Scenario . . . . .                                                      | 138        |
| Questions and Answers . . . . .                                              | 138        |
| Key Takeaways . . . . .                                                      | 141        |
| Suggested Readings . . . . .                                                 | 142        |
| <b>Investigational Product Discrepancies . . . . .</b>                       | <b>143</b> |
| <i>Ronit Reich-Slotky, PhD, MS, CABP(AABB)</i>                               |            |
| Case Scenario . . . . .                                                      | 143        |
| Questions and Answers . . . . .                                              | 144        |
| Key Takeaways . . . . .                                                      | 147        |
| Suggested Readings . . . . .                                                 | 147        |

## MANAGEMENT

### **Emergency Management (Weather Preparedness) . . . . . 149**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 149 |
| Questions and Answers. . . . . | 149 |
| Key Takeaways . . . . .        | 152 |
| Suggested Readings. . . . .    | 152 |

### **Quality Preparedness—What Is the Cost? . . . . . 153**

*Vasiliki E. Kalodimou, BSc (Hons), MSc, PhD, CABP(H)(AABB),  
IARMES*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 153 |
| Questions and Answers. . . . . | 153 |
| Key Takeaways . . . . .        | 155 |
| Suggested Readings. . . . .    | 156 |

## REGULATIONS

### **Navigating the Transition from Routine Banking to Clinical Trial Manufacturing: A Regulatory and Operational Dilemma . . . . . 157**

*Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB),  
DABRM, FABRM*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 157 |
| Questions and Answers. . . . . | 158 |
| Key Takeaways . . . . .        | 162 |
| Suggested Readings. . . . .    | 163 |

### **Disposition of Remaining Cellular Product Following a Patient Death: A Request for Cremation . . . . . 164**

*Asawari (Asa) Bapat, MBBS, DBP, CPS, PGDHHM, CABP(H)(AABB),  
DABRM, FABRM*

|                                |     |
|--------------------------------|-----|
| Case Scenario . . . . .        | 164 |
| Questions and Answers. . . . . | 164 |
| Key Takeaways . . . . .        | 167 |
| Suggested Readings. . . . .    | 168 |